Avidia, Inc. Initiates Clinical Trial Of Novel Inhibitor Of Interleukin-6 For Crohn's Disease
MOUNTAIN VIEW, Calif., Sept. 20 /PRNewswire/ -- Avidia Inc., a privately held biopharmaceutical company, today announced the initiation of and dosing of the first patient for a Phase I clinical trial of its novel drug candidate C326, an inhibitor of interleukin-6 for the treatment of Crohn's disease. C326 is the first in a new class of therapeutic proteins known as Avimer(TM) proteins.